Indoramin
 | |
| Systematic (IUPAC) name | |
|---|---|
| N-{1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl}benzamide | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Identifiers | |
26844-12-2  | |
| C02CA02 | |
| PubChem | CID 33625 |
| IUPHAR ligand | 501 |
| DrugBank |
DB08950 |
| ChemSpider |
31014  |
| UNII |
0Z802HMY7H |
| KEGG |
D04531 |
| ChEMBL |
CHEMBL279516 |
| Chemical data | |
| Formula | C22H25N3O |
| 347.454 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Indoramin (trade names Baratol and Doralese) is a piperidine antiadrenergic agent.
It is an alpha-1 selective adrenoceptor antagonist[1] with direct myocardial depression action; therefore, it results in no reflex tachycardia. It is also used in benign prostatic hyperplasia (BPH).[2]
It is commonly synthesized from tryptophol.[3]
Dosage
Indoramin is commonly prescribed as 20mg tablets when used in BPH.[4]
Side Effects
Drowsiness, dizziness, dry mouth, nasal congestion, headache, fatigue, weight gain, hypotension, postural hypotension, depression, problems with ejaculation, diarrhoea, nausea, increased need to pass urine, and palpitations.[5]
References
- ↑ Pierce V, Shepperson NB, Todd MH, Waterfall JF (February 1986). "Investigation into the cardioregulatory properties of the alpha 1-adrenoceptor blocker indoramin". Br. J. Pharmacol. 87 (2): 433–441. doi:10.1111/j.1476-5381.1986.tb10834.x. PMC 1916533. PMID 3955309.
- ↑ "Indoramin 20mg tablets". Medicines.org.uk. April 20, 2011. Retrieved September 30, 2012.
- ↑ Ullman's encyclopedia of Industrial Chemistry, Sixth Edition, 2002.
- ↑ "Indoramin hydrochloride". National Health Service (UK). Retrieved September 30, 2012.
- ↑ "Indoramin 20mg tablets". Medicines.org.uk. Retrieved September 30, 2012.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||